S&P 500   4,582.70 (-1.56%)
DOW   34,548.85 (-1.67%)
QQQ   393.67 (-1.51%)
AAPL   163.36 (+1.95%)
MSFT   330.27 (-1.89%)
FB   327.93 (-2.99%)
GOOGL   2,858.55 (-1.79%)
AMZN   3,505.88 (-1.56%)
TSLA   1,134.75 (-0.20%)
NVDA   322.84 (-3.27%)
BABA   126.92 (-3.56%)
NIO   38.95 (-3.73%)
CGC   10.41 (-5.88%)
AMD   157.54 (-2.70%)
GE   95.17 (-3.28%)
MU   84.93 (-1.40%)
T   22.73 (-4.86%)
F   19.32 (-1.78%)
DIS   144.22 (-2.43%)
ACB   6.23 (-3.26%)
AMC   34.06 (-7.55%)
PFE   53.83 (+2.73%)
BA   195.31 (-1.61%)
S&P 500   4,582.70 (-1.56%)
DOW   34,548.85 (-1.67%)
QQQ   393.67 (-1.51%)
AAPL   163.36 (+1.95%)
MSFT   330.27 (-1.89%)
FB   327.93 (-2.99%)
GOOGL   2,858.55 (-1.79%)
AMZN   3,505.88 (-1.56%)
TSLA   1,134.75 (-0.20%)
NVDA   322.84 (-3.27%)
BABA   126.92 (-3.56%)
NIO   38.95 (-3.73%)
CGC   10.41 (-5.88%)
AMD   157.54 (-2.70%)
GE   95.17 (-3.28%)
MU   84.93 (-1.40%)
T   22.73 (-4.86%)
F   19.32 (-1.78%)
DIS   144.22 (-2.43%)
ACB   6.23 (-3.26%)
AMC   34.06 (-7.55%)
PFE   53.83 (+2.73%)
BA   195.31 (-1.61%)
S&P 500   4,582.70 (-1.56%)
DOW   34,548.85 (-1.67%)
QQQ   393.67 (-1.51%)
AAPL   163.36 (+1.95%)
MSFT   330.27 (-1.89%)
FB   327.93 (-2.99%)
GOOGL   2,858.55 (-1.79%)
AMZN   3,505.88 (-1.56%)
TSLA   1,134.75 (-0.20%)
NVDA   322.84 (-3.27%)
BABA   126.92 (-3.56%)
NIO   38.95 (-3.73%)
CGC   10.41 (-5.88%)
AMD   157.54 (-2.70%)
GE   95.17 (-3.28%)
MU   84.93 (-1.40%)
T   22.73 (-4.86%)
F   19.32 (-1.78%)
DIS   144.22 (-2.43%)
ACB   6.23 (-3.26%)
AMC   34.06 (-7.55%)
PFE   53.83 (+2.73%)
BA   195.31 (-1.61%)
S&P 500   4,582.70 (-1.56%)
DOW   34,548.85 (-1.67%)
QQQ   393.67 (-1.51%)
AAPL   163.36 (+1.95%)
MSFT   330.27 (-1.89%)
FB   327.93 (-2.99%)
GOOGL   2,858.55 (-1.79%)
AMZN   3,505.88 (-1.56%)
TSLA   1,134.75 (-0.20%)
NVDA   322.84 (-3.27%)
BABA   126.92 (-3.56%)
NIO   38.95 (-3.73%)
CGC   10.41 (-5.88%)
AMD   157.54 (-2.70%)
GE   95.17 (-3.28%)
MU   84.93 (-1.40%)
T   22.73 (-4.86%)
F   19.32 (-1.78%)
DIS   144.22 (-2.43%)
ACB   6.23 (-3.26%)
AMC   34.06 (-7.55%)
PFE   53.83 (+2.73%)
BA   195.31 (-1.61%)
NASDAQ:MEDP

Medpace Stock Forecast, Price & News

$206.25
-2.84 (-1.36%)
(As of 11/30/2021 12:34 PM ET)
Add
Compare
Today's Range
$203.68
$210.39
50-Day Range
$182.74
$227.44
52-Week Range
$123.04
$231.00
Volume
4,482 shs
Average Volume
132,914 shs
Market Capitalization
$7.41 billion
P/E Ratio
42.61
Dividend Yield
N/A
Beta
1.33
30 days | 90 days | 365 days | Advanced Chart
Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.


Medpace logo

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Headlines

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO Sells $3,179,830.29 in Stock
November 29, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEDP
Employees
3,600
Year Founded
N/A

Sales & Book Value

Annual Sales
$925.92 million
Cash Flow
$4.68 per share
Book Value
$22.53 per share

Profitability

Net Income
$145.38 million
Pretax Margin
18.35%

Debt

Price-To-Earnings

Miscellaneous

Free Float
28,032,000
Market Cap
$7.41 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/24/2021
Today
11/30/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/21/2022

MarketRank

Overall MarketRank

2.39 out of 5 stars

Medical Sector

178th out of 1,390 stocks

Commercial Physical Research Industry

3rd out of 27 stocks

Analyst Opinion: 1.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 1.9 5 -4 -3 -2 -1 -












Medpace (NASDAQ:MEDP) Frequently Asked Questions

Is Medpace a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Medpace stock.
View analyst ratings for Medpace
or view top-rated stocks.

How has Medpace's stock been impacted by Coronavirus?

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MEDP stock has increased by 146.4% and is now trading at $206.11.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Medpace?

Medpace saw a decline in short interest in the month of October. As of October 29th, there was short interest totaling 740,400 shares, a decline of 17.6% from the October 14th total of 898,300 shares. Based on an average trading volume of 173,100 shares, the days-to-cover ratio is presently 4.3 days. Approximately 2.5% of the company's stock are short sold.
View Medpace's Short Interest
.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Medpace
.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) released its quarterly earnings results on Sunday, October, 24th. The company reported $1.29 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.07 by $0.22. The business had revenue of $295.57 million for the quarter, compared to analyst estimates of $291.55 million. Medpace had a net margin of 16.71% and a trailing twelve-month return on equity of 21.71%. The business's revenue was up 28.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.13 EPS.
View Medpace's earnings history
.

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY 2021 earnings guidance on Monday, November, 1st. The company provided EPS guidance of $4.660-$4.770 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.450. The company issued revenue guidance of $1.14 billion-$1.15 billion, compared to the consensus revenue estimate of $1.14 billion.

What price target have analysts set for MEDP?

3 brokers have issued 1-year price targets for Medpace's shares. Their forecasts range from $167.90 to $205.00. On average, they anticipate Medpace's share price to reach $190.97 in the next twelve months. This suggests that the stock has a possible downside of 7.3%.
View analysts' price targets for Medpace
or view top-rated stocks among Wall Street analysts.

Who are Medpace's key executives?

Medpace's management team includes the following people:

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace CEO August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among Medpace's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (10.45%), Wasatch Advisors Inc. (6.95%), Wellington Management Group LLP (3.18%), Invesco Ltd. (2.58%), Dimensional Fund Advisors LP (1.83%) and Boston Trust Walden Corp (1.48%). Company insiders that own Medpace stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends for Medpace
.

Which institutional investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Goldman Sachs Group Inc., Redwood Investments LLC, Schroder Investment Management Group, Jupiter Asset Management Ltd., Eagle Asset Management Inc., Monarch Partners Asset Management LLC, and Citadel Advisors LLC. Company insiders that have sold Medpace company stock in the last year include Ashley M Keating, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Stephen P Ewald, Susan E Burwig, and Tom C King.
View insider buying and selling activity for Medpace
or view top insider-selling stocks.

Which institutional investors are buying Medpace stock?

MEDP stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Vulcan Value Partners LLC, Stephens Investment Management Group LLC, Nordea Investment Management AB, Fuller & Thaler Asset Management Inc., AXA S.A., Wasatch Advisors Inc., and Assenagon Asset Management S.A.. Company insiders that have bought Medpace stock in the last two years include Peter J O'malley, and Wedbush Securities Inc.
View insider buying and selling activity for Medpace
or or view top insider-buying stocks.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $206.11.

How much money does Medpace make?

Medpace has a market capitalization of $7.41 billion and generates $925.92 million in revenue each year. The company earns $145.38 million in net income (profit) each year or $4.84 on an earnings per share basis.

How many employees does Medpace have?

Medpace employs 3,600 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

Where are Medpace's headquarters?

Medpace is headquartered at 5375 MEDPACE WAY, CINCINNATI OH, 45227.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at (513) 579-9911, via email at [email protected], or via fax at 513-579-0444.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.